In this issue:
- Recurrent VTE risk in subsegmental PE managed without anticoagulation
- Rivaroxaban for thromboprophylaxis after COVID-19 hospitalisation
- Milvexian for VTE prevention
- DAPT after percutaneous coronary intervention when bleeding risk is high
- FVIII expression after AAV gene transfer for haemophilia A
- Recurrent VTE and bleeding risks with apixaban vs. rivaroxaban
- DOACs with concomitant antiplatelets in VTE
- ICH incidence and mortality in haemophilia
- Targeted SERPIN: a dual-action antithrombotic agent
- VWF levels in the diagnosis of VWD
Please login below to download this issue (PDF)